Lack of effect of chronic hepatitis C virus infection on T-cell cytokine production in chronic hemodialysis patients

被引:7
作者
Rostaing, L
Borde, JS
Hasle, C
Bories, P
Allal, A
Abbal, M
Durand, D
机构
[1] Toulouse Univ Hosp, Nephrol Hemodialysis & Multiorgan Transplant Unit, Toulouse, France
[2] Toulouse Univ Hosp, Immunol Lab, Toulouse, France
关键词
flow cytometry; type 1 and type 2 cytokines; hemodialysis; hepatitis C virus; interleukin-2; interferon-gamma;
D O I
10.1159/000046247
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
It has been shown that chronic hemodialysis modifies, to some extent, the normal immune response by both T and B lymphocytes elicited by antigenic stimulation, e.g. by impairing the T-cell-dependent response after vaccination. A new technique, i.e. flow cytometry, enables to assess intracytoplasmically, at the single cell level, the production of a given cytokine. By using it, we studied in healthy volunteers (HV) and in chronic hemodialysis (CHD) patients, with respect to their hepatitis C virus (HCV) status, the production by the T lymphocytes of type 1, and type 2 cytokines. We studied the following cytokines (CK): IL-2, IL-4, IL-5, IL-6, IL-10, IFN-gamma and TNF-alpha in the T-cell lymphocytes (whole, CD4+ and CD8+). There were 13 HV and 59 CHD patients (36 HCV(-) and 23 HCV(+)). Amongst the latter, there were 32 men and 27 women, aged 59.5 +/- 2 years, undergoing CHD since 70 +/- 9.4 months. We found that: (1) the total number of lymphocytes as well as those expressing CD3, CD4, or CD19 were significantly decreased in CHD patients as compared to those from HV; (2) the total number of lymphocytes as well as their different subsets were similar in HCV(+) and in HCV(-) CHD patients; (3) the frequency of T-cell-expressing IL-5 or IL-10 was always low (<1%) in both HV and CHD groups; (4) overall in CHD patients, the mean percentages of T lymphocytes expressing IL-2, IL-4, IFN-<gamma> or TNF-alpha were respectively 31 +/- 13, 2.5 +/- 1.3, 28 +/- 12 and 34 +/- 11% and were not statistically different between HCV(+) and HCV(-) patients; (5) IL-2 was mainly produced by CD4+ T cells, whereas IFN-gamma was produced by CD8+ T cells, in both HV and CHD groups, and (6) the lymphocytes of CHD patients produced significantly more IL-2 and IL-4 than those from HV, suggesting an activation of their T lymphocytes. We conclude that using the cytokine flow cytometry assay, our study demonstrated that in HCV(+) CHD patients, as opposed to what has been described for HCV(+) patients with normal renal function, there was no impairment in the production of type 1 cytokines by peripheral blood mononuclear cells when compared to HCV(-) CHD patients. Conversely to HV, T lymphocytes from CHD patients are activated. Copyright (C) 2001 S. Karger AG, Basel.
引用
收藏
页码:194 / 199
页数:6
相关论文
共 34 条
[1]   The high prevalence of severe early posttransplant renal allograft pathology in hepatitis C positive recipients [J].
Cosio, FG ;
Sedmak, DD ;
Henry, ML ;
AlHaddad, C ;
Falkenhain, ME ;
Elkhammas, EA ;
Davies, EA ;
Bumgardner, GL ;
Ferguson, RM .
TRANSPLANTATION, 1996, 62 (08) :1054-1059
[2]  
Descamps-Latscha B, 1993, Curr Opin Nephrol Hypertens, V2, P883, DOI 10.1097/00041552-199311000-00005
[3]   CLONAL B-CELL EXPANSIONS IN PERIPHERAL-BLOOD OF HCV-INFECTED PATIENTS [J].
FRANZIN, F ;
EFREMOV, DG ;
POZZATO, G ;
TULISSI, P ;
BATISTA, F ;
BURRONE, OR .
BRITISH JOURNAL OF HAEMATOLOGY, 1995, 90 (03) :548-552
[4]   Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years [J].
Hanafusa, T ;
Ichikawa, Y ;
Kishikawa, H ;
Kyo, M ;
Fukunishi, T ;
Kokado, Y ;
Okuyama, A ;
Shinji, Y ;
Nagano, S .
TRANSPLANTATION, 1998, 66 (04) :471-476
[5]  
Izopet J, 1999, J MED VIROL, V58, P139, DOI 10.1002/(SICI)1096-9071(199906)58:2&lt
[6]  
139::AID-JMV7&gt
[7]  
3.0.CO
[8]  
2-7
[9]   DETECTION OF INTRACELLULAR CYTOKINES BY FLOW-CYTOMETRY [J].
JUNG, T ;
SCHAUER, U ;
HEUSSER, C ;
NEUMANN, C ;
RIEGER, C .
JOURNAL OF IMMUNOLOGICAL METHODS, 1993, 159 (1-2) :197-207
[10]   Initiation of hemodialysis treatment leads to improvement of T-cell activation in patients with end-stage renal disease [J].
Kaul, H ;
Girndt, M ;
Sester, U ;
Sester, M ;
Köhler, H .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 35 (04) :611-616